GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (TSXV:CYTO) » Definitions » Return-on-Tangible-Asset

Cytophage Technologies (TSXV:CYTO) Return-on-Tangible-Asset : -106.43% (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Cytophage Technologies Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Cytophage Technologies's annualized Net Income for the quarter that ended in Mar. 2025 was C$-4.64 Mil. Cytophage Technologies's average total tangible assets for the quarter that ended in Mar. 2025 was C$4.36 Mil. Therefore, Cytophage Technologies's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 was -106.43%.

The historical rank and industry rank for Cytophage Technologies's Return-on-Tangible-Asset or its related term are showing as below:

TSXV:CYTO' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -151.49   Med: -78.49   Max: -14.83
Current: -76.65

During the past 4 years, Cytophage Technologies's highest Return-on-Tangible-Asset was -14.83%. The lowest was -151.49%. And the median was -78.49%.

TSXV:CYTO's Return-on-Tangible-Asset is ranked worse than
71.71% of 1499 companies
in the Biotechnology industry
Industry Median: -36.14 vs TSXV:CYTO: -76.65

Cytophage Technologies Return-on-Tangible-Asset Historical Data

The historical data trend for Cytophage Technologies's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytophage Technologies Return-on-Tangible-Asset Chart

Cytophage Technologies Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Asset
-55.47 -14.83 -101.50 -151.49

Cytophage Technologies Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -241.56 -62.12 -64.77 -89.78 -106.43

Competitive Comparison of Cytophage Technologies's Return-on-Tangible-Asset

For the Biotechnology subindustry, Cytophage Technologies's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cytophage Technologies's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytophage Technologies's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Cytophage Technologies's Return-on-Tangible-Asset falls into.


;
;

Cytophage Technologies Return-on-Tangible-Asset Calculation

Cytophage Technologies's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-7.863/( (5.443+4.938)/ 2 )
=-7.863/5.1905
=-151.49 %

Cytophage Technologies's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=-4.64/( (4.938+3.781)/ 2 )
=-4.64/4.3595
=-106.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2025) net income data.


Cytophage Technologies  (TSXV:CYTO) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Cytophage Technologies Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Cytophage Technologies's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Cytophage Technologies Business Description

Traded in Other Exchanges
Address
200A - 400 Fort Whyte Way, Oak Bluff, Oak Bluff, MB, CAN, R4G 0B1
Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria company generates phages to address specific bacterial infections, including strains resistant to antibiotics.

Cytophage Technologies Headlines

No Headlines